Maryland Technology Development Corp.’s board of directors elected four new executive officers, including a new chairman.
Francis Smyth, CEO Century Engineering, has been named chair. He replaces former chairman Newt Fowler, an attorney from Womble Carlyle, who will remain on the board.
Marriott is branching out from hotels into the world of travel experiences in an innovative collaboration between Accenture and Incubator 1776.
The Travel Experience Incubator is a 12-week programme commencing on 12 September which has already received 165 applicants, from which six will be selected to take part in an ideas competition.
Women Building Bio: the XX factor is a day long conference to recognize and learn from leading women in the bioscience industry as pioneers paving the path to success. These women have faced their own unique challenges and carved out lasting legacies.
This day will catalyze the formation of a diverse network. It is a convergence of academia and industry, men and women, researchers and innovators, professionals and decision-makers gathering together to build relationships. This day long conference provides extraordinary opportunities to exchange new ideas, highlight areas of bioscience and research opportunities, and find partners for future collaboration.
GlaxoSmithKline is scrapping more than 30 drug development programs. The major cull of pipeline prospects will see GSK focus 80% of its R&D budget on the top candidates in four therapeutic areas and potentially exit the rare disease space.
The Inova Personalized Health Accelerator (IPHA) announced today that health and biosciences industry veteran Michael Thomas has been appointed Director of the Accelerator. Prior to joining Inova, Michael was founder and CEO of Appian Partners, an Annapolis life sciences consulting practice. His med-tech experience has spanned several early stage, growth stage, and turn-around ventures as CEO of Appian Partners, ReGear Life Sciences, NuSomnea, Tanzen Medical, Mommy’s Medicine Cabinet, Appian Medical, iSonea, and NovaSom. He also served on the board of directors for AdvaMed and Circadiance. He started his career in the pharmaceutical industry with Merck & Company and GlaxoSmithKline. Michael earned a BS in Microbiology from Cornell University.
In the run up to the inaugural Techweek Washington D.C., presented this year by AARP and held Oct. 2-6, Techweek today announced the Techweek100, honoring leading technology-focused firms in the D.C. area, as selected by an Executive Advisory Board comprised of 10 D.C.-based tech leaders.
A number of local movers and shakers with ties to Johns Hopkins have landed on the “40 Under 40” list published by the Baltimore Business Journal.
The journal’s annual list takes note of “innovators, professionals, and entrepreneurs in Greater Baltimore who have already made great strides before the age of 40,” including developers, CEOs, educators, and nonprofit founders. A Nov. 16 ceremony will celebrate this year’s b
The Inova Personalized Health Accelerator (IPHA) announced today that health and biosciences industry veteran Michael Thomas has been appointed Director of the Accelerator. Prior to joining Inova, Michael was founder and CEO of Appian Partners, an Annapolis life sciences consulting practice. His med-tech experience has spanned several early stage, growth stage, and turn-around ventures as CEO of Appian Partners, ReGear Life Sciences, NuSomnea, Tanzen Medical, Mommy’s Medicine Cabinet, Appian Medical, iSonea, and NovaSom. He also served on the board of directors for AdvaMed and Circadiance. He started his career in the pharmaceutical industry with Merck & Company and GlaxoSmithKline. Michael earned a BS in Microbiology from Cornell University.
Dimension Therapeutics has agreed to be acquired by RegenxBio, the gene therapy developer that originally helped form the company four years ago.
RegenxBio (NASDAQ: RGNX), based in Rockville, MD, will pay $3.41 per share in the all-stock deal valued at approximately $86 million. By comparison, Cambridge, MA-based Dimension (NASDAQ: DMTX) went public at $13 per share in 2015. Dimension’s closing stock price on Thursday was $1.20.
The academic biomedical research community is a hub of employment, economic productivity, and scientific progress. Academic research institutions are drivers of economic development in their local and state economies and, by extension, the national economy. Beyond the economic input that the academic biomedical research community both receives and provides, it generates knowledge that in turn affects society in myriad ways.
